

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT07193511

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Avenzo Therapeutics, Inc.
Enrollment	355 participants

Key Eligibility Criteria

Inclusion (5)

- Patient must be an adult, 18 years of age and older with an Eastern Cooperative Oncology Group (ECOG) Performance Status of d 1 and a life expectancy of \> 3 months.
- Patients with histologically or cytologically confirmed locally advanced/metastatic malignancies for tumor types of preferred indications:
 - o Locally advanced or metastatic urothelial cancer and other solid tumors (as specified in the protocol).
- Measurable disease as assessed by Investigator using RECIST v1.1.
- Agree to provide molecular test report results to confirm eligibility and archival tumor samples and/or fresh biopsy, as applicable.

Exclusion (6)

- Patients with active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate if they are radiologically stable for at least 4 weeks prior to the first dose of this study and do not require steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated.
- Prior Stevens-Johnson syndrome/toxic epidermal necrolysis.
- History of drug-induced interstitial lung disease (ILD).
- History of any serious cardiovascular condition.
- Infection requiring IV antibiotics, antivirals, or antifungals within 2 weeks prior to first dose.

... and 1 more (see full listing online)

Locations (8 total)

Avenzo Therapeutics Recruiting Site, Orlando, Florida, United States
Avenzo Therapeutics Recruiting Site, Boston, Massachusetts, United States
Avenzo Therapeutics Recruiting Site, New York, New York, United States
... and 5 more locations